Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

Dr Robert Risinger, chief medical officer of BioXcel Therapeutics, said: “We believe the recent FDA approval of BXCL501 for the acute treatment of agitation associated with schizophrenia or bipolar 1 or

Latest news

More from news
Approximately 30 fully matching, plus 236 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    year. We’re talking about the lawsuits J&J is facing claiming damages as a result of using its products, including opioid painkillers, Baby Powder talc and its schizophrenia drug Risperdal

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    for opioid addiction, and the long-acting injectable Perseris for schizophrenia in adults, which got FDA approval this year. ... of other drugs that can make it difficult for schizophrenia patients to trust and adhere to regimes.

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

More from intelligence
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....